![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Barrier Therapeutics Acquires U.S. and Canadian Rights to Solage
Barrier Therapeutics Acquires U.S. and Canadian Rights to Solage
Barrier Therapeutics, a pharmaceutical company developing products in the field of dermatology, has announced the acquisition of the U.S. and Canadian rights to Solage (mequinol 2 percent, tretinoin 0.01 percent) Topical Solution from Moreland Enterprises. Under the terms of the acquisition, Barrier made an initial cash payment of $3 million and will make future payments totaling up to an additional $2 million, depending upon future sales of the product.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=18944720&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct